Synaptopodin-2 plays an important role in the metastasis of breast cancer via PI3K/Akt/mTOR pathway
Authors Xia E, Zhou X, Bhandari A, Zhang X, Wang O
Received 16 January 2018
Accepted for publication 24 April 2018
Published 18 June 2018 Volume 2018:10 Pages 1575—1583
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Lu-Zhe Sun
Erjie Xia,* Xiaofen Zhou,* Adheesh Bhandari, Xiaohua Zhang, Ouchen Wang
Department of Thyroid & Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Introduction: Synaptopodin 2 (SYNPO2) is a functioning protein. It has been detected in many malignancies. But the relation between SYNPO2 and breast cancer (BC) is unclear.
Materials and methods: In this study, we explored the expression and function of SYNPO2 in BC. We found that SYNPO2 gene in BC was downregulated at the transcriptional level in both validated and TCGA cohorts.
Results: The results revealed that age, lymph node metastasis, and clinical stage in the validated cohort were related to the expression of SYNPO2 negatively. Kaplan–Meier analysis showed that patients with lower SYNPO2 expression had a worse overall survival.
Discussion: We found that migration and invasion were promoted after knocking down SYNPO2 in MCF-7, MDA-MB-231, BT-549, and MDA-MB-468. Meanwhile, knockdown of SYNPO2 could enhance PI3K/AKT/mTOR signaling pathway, which may induce migration and invasion. Our findings reveal that SYNPO2 was associated with BC.
Keywords: breast cancer, SYNPO2, metastasis, PI3K/AKT/mTOR signaling pathway
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]